Actively Recruiting
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
Led by Texas Retina Associates · Updated on 2025-08-11
30
Participants Needed
1
Research Sites
216 weeks
Total Duration
On this page
Sponsors
T
Texas Retina Associates
Lead Sponsor
E
Eye Point Pharmaceuticals
Collaborating Sponsor
AI-Summary
What this Trial Is About
The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
CONDITIONS
Official Title
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or non-pregnant female in good general health at least 18 years of age
- Able to understand and provide written informed consent and sign a HIPAA form
- Willing and able to follow scheduled visits, treatment plans, laboratory tests, and other study procedures
- Diagnosed with chronic unilateral or bilateral noninfectious posterior segment inflammation, with or without anterior uveitis, showing response to at least one prior corticosteroid treatment
- Presence of active posterior segment inflammation as determined by the investigator
- Vitreous haze grade of 2 or greater based on SUN criteria
- Less than 10 anterior chamber cells per high power field by slit lamp exam
- Not planning elective eye surgery during the study
You will not qualify if you...
- Known allergy to any components of YUTIQ
- Female subjects who are pregnant or breastfeeding
- Any acute or chronic medical or psychiatric condition that may prevent safe participation
- History of anterior uveitis only without posterior segment involvement
- Presence of vitreous hemorrhage
- Uveitis caused by infection
- Intraocular inflammation from causes other than noninfectious uveitis (e.g., intraocular lymphoma)
- Current infectious diseases of cornea, conjunctiva, mycobacterial or fungal eye infections
- Presence of anterior chamber intraocular lens or rupture of posterior lens capsule
- Diagnosis of any glaucoma or ocular hypertension at screening unless controlled with 2 or fewer IOP-lowering medications or stable after surgery
- Intraocular pressure over 21 mmHg or use of more than 2 IOP-lowering drugs in study eye
- Eye surgery within 12 weeks before study start
- Inability to attend all scheduled visits during the 12-month study
- Significant media opacity preventing retina and vitreous evaluation in study eye
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Texas Retina Associates
Plano, Texas, United States, 75075
Actively Recruiting
Research Team
T
Tara Keesling, COA
CONTACT
J
Jodi Creighton
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here